AML with NPM1 mutation is currently treated with the administration of several cycles of an anthracycline (daunorubicin, doxorubicin or others) plus cytarabine.40 Patients carrying NPM1 mutation without the concomitant FLT3-ITD alteration have good prognosis while, for the latter, chemotherapy is less effective. Here, FLT3 is linked to acute myeloid leukemia.